The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Shares of TRIB opened at $0.86 on Thursday. Trinity Biotech has a one year low of $0.74 and a one year high of $3.55. The company has a market cap of $15.56 million, a PE ratio of -0.38 and a beta ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for ...

Trinity Biotech's latest pre-pivotal trial involved 30 diabetic participants, primarily individuals with Type 1 diabetes, each of whom wore multiple sensors over a 15-day period. As previously ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its ...